Klinikum Oberberg

Jun 4, 2024 | link.springer.com | Justus Liebig |Klinikum Oberberg

IntroductionMyasthenia gravis (MG) is a rare antibody-mediated disorder of the neuromuscular junction with an annual incidence ranging from 0.5 to 3 per 100.000 patients [4]. A fluctuating, activity-dependent weakness predominantly affects ocular, bulbar, and/or limb and trunk skeletal muscles. Treatment comprises symptomatic (cholinesterase inhibitors) as well as immunosuppressive treatment.